Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2010 / Article

Open Access

Volume 3 |Article ID 938285 | https://doi.org/10.4161/oxim.3.2.11148

Sho-ichi Yamagishi, Takanori Matsui, "Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy", Oxidative Medicine and Cellular Longevity, vol. 3, Article ID 938285, 8 pages, 2010. https://doi.org/10.4161/oxim.3.2.11148

Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy

Received05 Jan 2010
Revised07 Jan 2010
Accepted07 Jan 2010

Abstract

About 246 million people worldwide had diabetes in 2007. The global figure of people with diabetes is projected to increase to 370 million in 2030. As the prevalence of diabetes has risen to epidemic proportions worldwide, diabetic nephropathy has become one of the most challenging health problems. Therapeutic options such as strict blood glucose and blood pressure controls are effective for preventing diabetic nephropathy, but are far from satisfactory, and the number of diabetic patients on end-stage renal disease is still increasing. Therefore, a novel therapeutic strategy that could halt the progression of diabetic nephropathy should be developed. There is accumulating evidence that advanced glycation end products (AGEs), senescent macroprotein derivatives formed at an accelerated rate under diabetes, play a role in diabetic nephropathy via oxidative stress generation. In this paper, we review the pathophysiological role of AGEs and their receptor (RAGE)-oxidative stress system in diabetic nephropathy.

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views1526
Downloads3213
Citations